This phase II trial studies how well daratumumab works in treating participants with multiple myeloma that has come back after stem cell transplant. Immunotherapy with daratumumab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread.
The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.
The following criteria is provided for health care professionals.
There are no resources, links or videos to display for this clinical trial.